Genmab — December 2019
-
Novartis still hasn't solved its CAR-T manufacturing issues https://www.biopharmadive.com/news/novartis-kymriah-car-t-manufacturing-difficulties-cell-viability/568830/
-
Absolutely agree EL. Can't see why anyone should be disappointed. Some is taking profit now, and so what. The case is as strong as never before.
-
No one could have expected more - I didn´t
-
Mange var også vældig fortrøstningsfuld i 2017, indtil kursen var faldet 500-600 kurspoint..... jeg tror også, at investorer bliver skuffet, hvis de igennem flere er bleven lovet en aftale, og den fortsat ikke er i hus. Det kan godt være direktøren var meget optimistisk på konferencen, men men men....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind